Agilent Technologies Inc
NYSE:A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Agilent Technologies Inc
NYSE:A
|
US |
|
Harvey Norman Holdings Ltd
ASX:HVN
|
AU |
|
Equifax Inc
NYSE:EFX
|
US |
|
Muyuan Foods Co Ltd
SZSE:002714
|
CN |
|
Vestas Wind Systems A/S
CSE:VWS
|
DK |
|
People's Insurance Company Group of China Ltd
SSE:601319
|
CN |
|
E
|
Eprcomunicazione SpA Societa Benefit
MIL:EPRB
|
IT |
|
A
|
Asset World Corp PCL
SET:AWC
|
TH |
|
Constellation Brands Inc
NYSE:STZ
|
US |
|
Tencent Music Entertainment Group
NYSE:TME
|
CN |
Agilent Technologies Inc
Agilent Technologies makes the tools that scientists and lab technicians use to test, measure, and analyze samples. Its products include analytical instruments, lab software, consumables, and repair and support services. Customers use them in drug development, clinical and diagnostic labs, food safety, environmental testing, and chemical research. The company sells equipment such as chromatography and spectroscopy systems, along with the parts and chemicals that those systems need to keep running. It also earns money from service contracts, maintenance, and replacement consumables, which creates repeat business after the initial sale. A large part of Agilent’s revenue comes from labs that need reliable instruments and ongoing support rather than one-time purchases. Agilent sits in the middle of the scientific testing value chain: it does not usually discover the medicines or run the labs, but it provides the core tools those customers depend on. That makes its business different from many industrial companies because demand is tied to long-running needs for testing, quality control, and research rather than a single end product.
Agilent Technologies makes the tools that scientists and lab technicians use to test, measure, and analyze samples. Its products include analytical instruments, lab software, consumables, and repair and support services. Customers use them in drug development, clinical and diagnostic labs, food safety, environmental testing, and chemical research.
The company sells equipment such as chromatography and spectroscopy systems, along with the parts and chemicals that those systems need to keep running. It also earns money from service contracts, maintenance, and replacement consumables, which creates repeat business after the initial sale. A large part of Agilent’s revenue comes from labs that need reliable instruments and ongoing support rather than one-time purchases.
Agilent sits in the middle of the scientific testing value chain: it does not usually discover the medicines or run the labs, but it provides the core tools those customers depend on. That makes its business different from many industrial companies because demand is tied to long-running needs for testing, quality control, and research rather than a single end product.
Revenue: Q1 revenue was $1.8 billion, up 4.4% on a core basis and within guidance, despite a $10 million hit from a U.S. winter storm.
Margins: Operating margin was 24.6%, in line with expectations; gross margin was 53.7%, down 100 bps YoY, mainly due to tariff headwinds.
EPS: Q1 EPS was $1.36, up 4% YoY and within guidance.
Guidance Maintained: Full-year core revenue growth guidance remains 4% to 6%; EPS guidance raised slightly to $5.90–$6.04 due to favorable currency.
Q2 Outlook: Q2 revenue guidance is $1.79–$1.82 billion (core growth 4%–5.5%); EPS expected at $1.39–$1.42, up 7% at midpoint.
End Market Trends: Strong growth in pharma, chemicals/advanced materials, and diagnostics; continued weakness in academia/government and food.
China: China revenue grew 6%, helped by a small stimulus, with expectations for mid- to high-single-digit growth ahead.
Tariffs: Tariff headwinds continue but are expected to be fully mitigated by the second half of the year; recent policy changes do not trigger a guidance change.
Management
Rodney Gonsalves is the Vice President and Chief Accounting Officer at Agilent Technologies Inc. He specializes in finance and accounting functions, including financial reporting, auditing, and compliance. Gonsalves has extensive experience in leading and managing finance teams, focusing on delivering financial insights and maintaining rigorous standards of accuracy and efficiency. He plays a critical role in Agilent Technologies' financial health, ensuring that all accounting practices adhere to the highest standards and regulations. Prior to his role at Agilent, he gathered substantial experience in varied finance roles across different organizations, contributing significantly to strategic financial planning and execution.
John Kohl is the Senior Vice President, General Counsel, and Secretary at Agilent Technologies, Inc. He plays a pivotal role in overseeing the global legal affairs of the company, providing strategic guidance on legal, regulatory, and compliance matters. Kohl has been instrumental in shaping and navigating Agilent's legal strategies and policies, ensuring adherence to increasing regulatory requirements across various markets. With a robust legal background and significant experience in the technology and healthcare sectors, John Kohl has contributed to Agilent's growth and success in the industry. His leadership extends beyond legal counsel, as he participates in key executive decisions, corporate governance, and risk management initiatives. Kohl joined Agilent Technologies with a wealth of experience gained from his previous roles in prestigious law firms and other corporations. His expertise spans various areas, including intellectual property, mergers and acquisitions, and legal risk management, making him a valuable asset to Agilent's executive team.
With a robust legal background and significant experience in the technology and healthcare sectors, John Kohl has contributed to Agilent's growth and success in the industry. His leadership extends beyond legal counsel, as he participates in key executive decisions, corporate governance, and risk management initiatives.
Kohl joined Agilent Technologies with a wealth of experience gained from his previous roles in prestigious law firms and other corporations. His expertise spans various areas, including intellectual property, mergers and acquisitions, and legal risk management, making him a valuable asset to Agilent's executive team.
Bret M. DiMarco serves as the Senior Vice President, General Counsel, and Secretary of Agilent Technologies Inc. In his role, DiMarco oversees Agilent's global legal, intellectual property, and compliance functions. He plays a critical role in guiding the company through complex legal landscapes, ensuring compliance with regulations, and protecting Agilent's intellectual property assets. DiMarco's leadership is instrumental in supporting Agilent's business goals and maintaining its ethical standards across its global operations. His extensive experience and expertise in legal affairs contribute significantly to the company's strategic initiatives and growth.
Dominique P. Grau is a notable executive at Agilent Technologies Inc. He serves as the Senior Vice President of Quality and Regulatory Affairs for the company. In his role, he oversees global quality assurance, regulatory affairs, and compliance functions. His responsibilities include ensuring that Agilent’s products adhere to the highest quality standards and meet regulatory requirements across different markets. Mr. Grau has extensive experience in quality and regulatory roles, contributing significantly to the life sciences and diagnostics sectors. His expertise is integral to maintaining Agilent's reputation for excellence in providing trusted analytical solutions and ensuring the company’s products contribute to customer success. In addition to his current role, Dominique P. Grau's career includes various leadership positions, where he has demonstrated his adeptness at managing complex regulatory landscapes and driving improvement initiatives. His educational background and career trajectory underline his commitment to quality and compliance, positioning him as a key figure in Agilent's leadership team.
Mr. Grau has extensive experience in quality and regulatory roles, contributing significantly to the life sciences and diagnostics sectors. His expertise is integral to maintaining Agilent's reputation for excellence in providing trusted analytical solutions and ensuring the company’s products contribute to customer success.
In addition to his current role, Dominique P. Grau's career includes various leadership positions, where he has demonstrated his adeptness at managing complex regulatory landscapes and driving improvement initiatives. His educational background and career trajectory underline his commitment to quality and compliance, positioning him as a key figure in Agilent's leadership team.
Jenipher E. Dalton is an executive at Agilent Technologies Inc., where she holds the position of Vice President, Assistant General Counsel, and Assistant Secretary. In her role, Dalton plays a crucial part in overseeing legal matters and corporate governance at Agilent, a leading global company in the life sciences, diagnostics, and applied chemical markets. Her responsibilities typically involve managing legal risks, supporting business strategies, providing legal guidance on transactions, and ensuring regulatory compliance. Through her expertise and leadership, Dalton contributes to Agilent’s mission of advancing the quality of life by providing cutting-edge technology solutions.
Philip Binns is recognized for his role at Agilent Technologies, where he has made significant contributions. Serving as Senior Vice President, he oversees the Chemical & Energy, Food, and Pharma business unit in the company's Life Sciences and Applied Markets Group. Under his leadership, these sectors have successfully advanced in developing and deploying innovative solutions that meet varied industry needs. Binns' strategic insights and management acumen have played a crucial role in navigating complex market landscapes and expanding Agilent's position within these critical industries. His extensive experience in technology and market strategy continues to serve as a valuable asset to Agilent Technologies.
Dr. Simon May is a prominent figure at Agilent Technologies Inc., where he holds a significant leadership role. As of the latest information, he serves as the Vice President and General Manager of the Mass Spectrometry Division. Dr. May is responsible for overseeing the strategic direction, development, and global operations of Agilent’s mass spectrometry business, a core area within the life sciences and applied markets. With a strong academic background in chemistry, Dr. May has extensive expertise in analytical instrumentation, having garnered numerous years of experience in the field. Before joining Agilent, he held various roles that contributed to his deep understanding of scientific research and development, as well as business management. Throughout his career at Agilent, Dr. May has been instrumental in driving innovation and advancing the company’s technological capabilities in mass spectrometry. His leadership has been key to enhancing Agilent's position as a leader in providing solutions for complex analytical challenges across various industries, including pharmaceuticals, environmental, and food safety sectors. Dr. May's contributions are recognized within the scientific community and industry, noted for his commitment to promoting scientific excellence and fostering collaborative relationships to advance the capabilities and applications of mass spectrometry technologies.
With a strong academic background in chemistry, Dr. May has extensive expertise in analytical instrumentation, having garnered numerous years of experience in the field. Before joining Agilent, he held various roles that contributed to his deep understanding of scientific research and development, as well as business management.
Throughout his career at Agilent, Dr. May has been instrumental in driving innovation and advancing the company’s technological capabilities in mass spectrometry. His leadership has been key to enhancing Agilent's position as a leader in providing solutions for complex analytical challenges across various industries, including pharmaceuticals, environmental, and food safety sectors.
Dr. May's contributions are recognized within the scientific community and industry, noted for his commitment to promoting scientific excellence and fostering collaborative relationships to advance the capabilities and applications of mass spectrometry technologies.
